Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Clinical Nephrology
|
August 1, 1990
Diffuse proliferative lupus nephritis: long-term observations in patients treated with ancrod
S Hariharan, V E Pollak, K S Kant, et al.
Clinical and Experimental Immunology
|
October 1, 1977
Lymphocytotoxins in epileptic patients receiving phenytoin
B S Ooi, K S Kant, I B Hanenson, et al.
The Journal of Laboratory and Clinical Medicine
|
January 1, 1985
Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis
P Glas-Greenwalt, K S Kant, A Dosekun, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
March 1, 1992
Protein S deficiency and skin necrosis associated with continuous ambulatory peritoneal dialysis
K S Kant, H I Glueck, M C Coots, et al.
Medicine
|
January 1, 1994
Pancreatitis in patients with end-stage renal disease
B Padilla, V E Pollak, A Pesce, et al.
Archives of Internal Medicine
|
August 1, 1985
Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants
H I Glueck, K S Kant, M A Weiss, et al.
The Journal of Laboratory and Clinical Medicine
|
January 1, 1985
Lupus nephritis with thrombosis and abnormal fibrinolysis: effect of ancrod
K S Kant, V E Pollak, A Dosekun, et al.
Clinical Nephrology
|
October 1, 1985
Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin)
X H Du, P Glas-Greenwalt, K S Kant, et al.
Thrombosis Research
|
September 15, 1982
Deficiency of a plasma factor stimulating vascular prostacyclin generation in patients with lupus nephritis and glomerular thrombi and its correction by ancrod: in-vivo and in-vitro observations
K S Kant, A K Dosekun, K G Chandran, et al.
The Journal of Laboratory and Clinical Medicine
|
November 1, 1986
Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura
P Glas-Greenwalt, J M Hall, T W Panke, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Clinical Nephrology
|
August 1, 1990
Diffuse proliferative lupus nephritis: long-term observations in patients treated with ancrod
S Hariharan, V E Pollak, K S Kant, et al.
Clinical and Experimental Immunology
|
October 1, 1977
Lymphocytotoxins in epileptic patients receiving phenytoin
B S Ooi, K S Kant, I B Hanenson, et al.
The Journal of Laboratory and Clinical Medicine
|
January 1, 1985
Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis
P Glas-Greenwalt, K S Kant, A Dosekun, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
March 1, 1992
Protein S deficiency and skin necrosis associated with continuous ambulatory peritoneal dialysis
K S Kant, H I Glueck, M C Coots, et al.
Medicine
|
January 1, 1994
Pancreatitis in patients with end-stage renal disease
B Padilla, V E Pollak, A Pesce, et al.
Archives of Internal Medicine
|
August 1, 1985
Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants
H I Glueck, K S Kant, M A Weiss, et al.
The Journal of Laboratory and Clinical Medicine
|
January 1, 1985
Lupus nephritis with thrombosis and abnormal fibrinolysis: effect of ancrod
K S Kant, V E Pollak, A Dosekun, et al.
Clinical Nephrology
|
October 1, 1985
Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin)
X H Du, P Glas-Greenwalt, K S Kant, et al.
Thrombosis Research
|
September 15, 1982
Deficiency of a plasma factor stimulating vascular prostacyclin generation in patients with lupus nephritis and glomerular thrombi and its correction by ancrod: in-vivo and in-vitro observations
K S Kant, A K Dosekun, K G Chandran, et al.
The Journal of Laboratory and Clinical Medicine
|
November 1, 1986
Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura
P Glas-Greenwalt, J M Hall, T W Panke, et al.
Page
of 3